I went from 0-60 on prostate cancer in a few days last year when my dad was diagnosed at stage 4 (he’s much better now). I was surprised to find that getting in

I went from 0-60 on prostate cancer in a few days last year when my dad was diagnosed at stage 4 (he’s much better now). I was surprised to find that getting into clinical trials is not so difficult and they’re well catalogued; as an example, check out https://www.cancer.gov/about-cancer/treatment/clinical-trials https://www.cancer.gov/about-cancer/treatment/clinical-trial.... Generally, it seems that promising therapies advance pretty quickly, and oncologists seem to stay current. So, I don’t think there’s quite the level of bureaucracy as you may suspect. That said, with trials there’s a good chance a patient will wind up in the control group (sad trombone), and a lot of new treatments don’t work all that well, or merely extend survival for a few months in exchange for several side effects. A LOT of trials are also simply studying the efficacy of the combination of known treatments; these trials are safer bets, but they’re also unlikely to provide one with a miracle. With immunotherapies, keep in mind that side effects during treatment can be severe and potentially fatal. Basically, if you have late stage cancer and treatment works, you almost die from the toxic effects of your immune system kicking into overdrive and blowing up all the tumor cells in a few days. There’s a ton of supportive therapy. If a new immunotherapy like the one in TFA showed promise, all the necessary supportive therapy acts as a limiter on rapid scale-up, even with perfect knowledge sharing and patient access.